Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

    Apr 30, 2026DOI: 10.1093/cid/ciaf732Journal ArticleCID

    Written by: Emmanuella Chinonso OsualaIvan Nicholas NkuhairweMarothi Peter LetsoaloKogieleum NaidooRubeshan PerumalJames F RooneyLubbe WiesnerRoeland E WasmannPaolo DentiKelly E DooleyAnushka NaidooINSIGHT Study Team

    Find these authors on Roon

    KD
    Dr. Kelly Dooley
    Mycobacterial Disease · Vanderbilt

    METHODS

    A prospective semi-intensive pharmacokinetic substudy was nested within the “INSTIs for the management of HIV-associated TB” (INSIGHT) phase 2b open-label randomized noncomparative controlled trial conducted in Durban, South Africa [14, 15]. The INSIGHT trial was designed to evaluate the efficacy, safety, and pharmacokinetics of BIC/FTC/TAF 50/200/25 mg (intervention arm) versus dolutegravir/TDF/lamivudine 50/300/300 mg (standard of care arm) for treatment of HIV-1 infection in participants with drug-susceptible TB on a rifampicin-based treatment. The study design has been previously described [14, 15].Participants randomized to the intervention arm who consented to the semi-intensive pharmacokinetic substudy were enrolled until the target sample size was achieved. The parent trial included adults ≥ 18 years of age, confirmed HIV positive (ART naive or treatment experienced with no exposure to ART within 3 months of study enrollment) with CD4 count ≥ 50 cells/µL, diagnosed with rifampicin-susceptible TB and/or on a first-line rifampicin-based TB treatment regimen. The sample size and sampling time points for the TAF pharmacokinetic substudy was adapted from the parent trial that explored bictegravir pharmacokinetics [14, 15].Ethical approval for the INSIGHT study was obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00001300/2020) and the Vanderbilt University Medical Center Institutional Review Board (222008). The study was registered on ClinicalTrials.gov with registration number NCT04734652.Participants received twice-daily BIC/FTC/TAF 50/200/25 mg regimen during TB treatment until two weeks post-TB treatment completion and then once-daily BIC/FTC/TAF until 48 weeks. TB treatment [fixed-dose rifampicin, isoniazid, pyrazinamide, and ethambutol (RHZE) during intensive phase and RH during continuation phase] was administered for ∼24 weeks according to the South Africa National treatment guidelines, and dosing was weight-based.Pharmacokinetic sampling was performed at weeks 4 and 12 on twice-daily BIC/FTC/TAF during rifampicin-based TB treatment and at week 32 (at least 2 weeks after TB treatment discontinuation) on once-daily BIC/FTC/TAF without rifampicin. Adherence to ART and TB treatment was measured using pill count, as well as participant self-reported diary entries for the three days prior to pharmacokinetic visit. Blood samples (plasma and dried blood spots [DBS]) were collected at predose, 1, 2, 4, 6, and 8–12 hours post an observed intake of BIC/FTC/TAF at weeks 4 and 12 and at predose, 1, 2, 4, 6–8, and 24–25 hours postdose at week 32.
    TAF and TFV concentrations were measured simultaneously from plasma samples using a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) method at the University of Cape Town [16]. TAF profiles were limited to 4 hours postdose given TAF's rapid elimination from the plasma. The lower limit of quantification (LLOQ) for both TAF and TFV was 0.500 ng/mL. The combined accuracy of the limit of quantification, low, medium, and high-quality controls of TAF and TFV were between 93.8% and 105.1%, with precision (%CV) <13%.
    Intracellular TFV-DP concentrations were quantified from DBS samples. For DBS preparation, 50 μL of whole blood was applied to Whatman 903 protein saver cards. Cards were dried at room temperature, for a minimum of 3 hours and stored in labeled plastic bags with desiccant at −80°C. DBS samples were assayed with a validated LC-MS/MS methods using an entire spot for the analysis and concentration converted to fmol per 3 mm punch after analysis [17].
    Pharmacokinetic parameters for TAF, TFV, and TFV-DP were determined with noncompartmental analysis using PKanalix2024R1 software [18]. The area under the concentration-time curve (AUC), maximum and trough concentrations (Cmax and Ctau), time to Cmax (Tmax) and average concentration (Cavg) were computed. The AUC was computed using the linear-up log-down trapezoidal method and extrapolated to the dosing interval (ie, 12 or 24 hours). For twice-daily dosing, AUC0-12 was multiplied by 2 for comparison with once-daily dosing AUC0-24h. For TAF, AUC0-4 was calculated from dose to the 4-hour sampling time point. All below the limit of quantification (BLQ) values before Tmax were imputed as zero, while those after Tmax were imputed as LLOQ/2. Parameters were reported as geometric means (GM) with coefficients of variation (CV%). The influence of rifampicin on the pharmacokinetics of TAF was calculated as geometric least square mean (GLSM) ratios and 90% confidence intervals, with once-daily TAF without rifampicin taken as the reference. GLSM ratios (90% CI) were computed using the PKanalix2024R1 software, which applies a linear model to log-transformed pharmacokinetic parameters. TFV concentrations were evaluated against the safety threshold of 160 ng/mL reported in the literature [19].
    Viral suppression was defined as the proportion of participants with HIV-1 RNA < 50 copies/mL at weeks 12, 24 (primary endpoint), and 48. Clinical and safety monitoring was done monthly until week 12, at week 24 and every 8 weeks thereafter, until week 48 or as clinically indicated. Laboratory and safety investigations including renal and hepatic biochemistry were assessed. Adverse events (AEs) were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [20].

    RESULTS

    Forty-three participants were enrolled in the pharmacokinetic substudy (Table 1; Supplementary Figure 1). Baseline characteristics of the substudy participants and participants in the overall intervention arm of the parent trial are shown in Table 1. Median (IQR) age and weight of substudy participants were 35 (30–39) years and 58 (52–65) kg; with 77% male, and 100% black. Median (IQR) eGFR was 121 (112–127) mL/min/1.73 m2. Fifteen participants (35%) had previous ART exposure; median (IQR) viral load and CD4 were 4.7 (4.0–5.4) log10copies/mL and 217 (122–380) cells/μL. One participant exited early from the study and did not contribute to the pharmacokinetic substudy, the remaining participants completed study follow-up. Participant characteristics during the pharmacokinetic visits are presented in Supplementary Table 1.
    Characteristics of Participants in the Semi-intensive Pharmacokinetic Substudy and Overall Intervention Arm of the INSIGHT Trial
    Data are n (%) or median (IQR) unless otherwise stated.
    Abbreviations: ART, antiretroviral therapy; BMI, body mass index; eGFR, estimated glomerular filtration rate; IQR, interquartile range; n, number of participants; RIF, rifampicin; TB, tuberculosis.
    aFour participants had nondetectable viral loads at baseline.
    Pharmacokinetic analyses for TAF and TFV were performed in 40 participants at two occasions during TB treatment and in 41 participants on one occasion post-TB treatment (Supplementary Figure 1). Three participants missed one visit (two missed visits were due to treatment holds with participants off ART and anti-TB treatment because of hepatotoxicity, and one due to hospitalization). Two pharmacokinetic profiles were excluded, one because of an anomalous pharmacokinetic curve (n = 1, TAF and TFV only), and one because of nonadherence (n = 1). A total of 121 profiles were evaluable for TAF and TFV and 122 profiles for TFV-DP both during and after TB treatment. Thirteen TAF samples were BLQ at the 4 hours time point [week 4 (n = 1), week 12 (n = 4) and week 32 (n = 8)].
    The pharmacokinetic profiles of plasma TAF, plasma TFV, and intracellular TFV-DP are shown in Figures 1 and 2 with pharmacokinetic parameters summarized in Table 2. The GM concentrations of plasma TAF and TFV were higher during twice-daily TAF with rifampicin (weeks 4 and 12) compared to once-daily TAF post-rifampicin (week 32). The GLSM ratios (90% CI) at weeks 4 and 12 relative to week 32 for TAF AUC0-4 were 3.23 (2.36–4.42) and 1.55 (1.13–2.13), while the ratios for Cmax were 2.78 (2.04–3.78) and 1.52 (1.12–2.07), respectively. For TFV, GLSM ratios (90% CI) at weeks 4 and 12 versus week 32 for AUC0-24 were 1.27 (1.10–1.48) and 1.24 (1.07–1.44), and for Cmax were 1.21 (1.06–1.38) and 1.23 (1.07–1.40), respectively.
    Geometric means of plasma TAF, TFV, and Intracellular TFV-DP concentration-time curves at each PK visit with their 95% confidence intervals. Abbreviations: BD, twice-daily; LLOQ, lower limit of quantification; QD, once-daily; RIF, rifampicin; TAF, tenofovir alafenamide; TFV, tenofovir; TFV-DP, tenofovir diphosphate.
    Boxplots of Plasma TAF AUC0-4, TFV AUC0-24 and Intracellular TFV-DP AUC0-24 at weeks 4 and 12 during twice-daily TAF with RIF and at week 32 during once-daily TAF without RIF. Abbreviations: AUC, area under the concentration-time curve; BD, twice-daily; QD, once-daily; RIF, rifampicin; TAF, tenofovir alafenamide; TFV, tenofovir; TFV-DP, tenofovir diphosphate.
    Pharmacokinetic Parameters of Plasma Tenofovir Alafenamide, Tenofovir, and Intracellular Tenofovir-diphosphate During Twice-daily Tenofovir Alafenamide coadministered With Rifampicin-based TB Treatment or Once-daily Tenofovir Alafenamide Given Alone
    TAF and TFV were assayed in plasma, while TFV-DP was intracellular (dried blood spots). Data are geometric means (CV%) except for Tmax, which is denoted as median (interquartile range).
    Abbreviations: AUC0-24, area under the concentration-time curve from 0 to 24 h; AUClast, area under the concentration-time curve from 0 to the last quantifiable sampling time point; BD, twice-daily; Cavg, average concentration from time 0 to the last quantifiable sampling time point (Tlast); CI, confidence interval; Cmax, maximum concentration; CV, coefficient of variation; GLSM ratio, geometric least square mean ratio; QD, once-daily; RIF, rifampicin; TAF, tenofovir alafenamide; Tlast, time from dosing to the last quantifiable sampling time point; TFV, tenofovir; TFV-DP, tenofovir diphosphate
    aAUC0-4 for TAF was calculated from dose to the 4-h sampling time point. For TAF 25 mg BD + RIF (weeks 4 and 12), only one of the two TAF profiles was available. AUC0-24 was calculated by multiplying the extrapolated AUC0-12 by 2 for TAF 25 mg BD + RIF. Ctau was calculated by extrapolating up to 12 and 24 h for BID and QD TAF 25 mg respectively. Cavg was calculated by dividing the AUClast by the Tlast.
    bGLSM ratio TFV Tmax: n = 35
    cTFV-DP concentrations were not at steady-state.
    dGLSM ratio TFV-DP Tmax: n = 23.
    Intracellular TFV-DP concentrations increased between weeks 4 and 12 during twice-daily TAF with rifampicin and then declined after transition to once-daily TAF. The GLSM ratios (90% CI) at weeks 4 and 12 compared to week 32 for AUC0–24 were 1.08 (0.93–1.26) and 1.32 (1.13–1.53), and for Cmax were 1.37 (1.19–1.57) and 1.63 (1.42–1.87), respectively. The intraindividual changes in AUC and visit-specific adherence for individuals with low TFV or TFV-DP AUC0-24 are shown in Supplementary Figure 2 and Supplementary Table 2.
    Efficacy and safety are reported for substudy participants. HIV-1 RNA viral load was < 50 copies/mL at the end of TB treatment (week 24) in 95% (95% CI 84–99) of participants. Grade 3 or higher renal AEs occurred in 2 (5%) participants (one participant had a grade 3 reduced creatinine clearance and eGFR value and second participant had only grade 3 reduced creatinine clearance). SAEs occurred in 4 (9%) participants, but none were deemed related to study treatment. There were no deaths, permanent study treatment discontinuations, or drug switches among the participants.

    DISCUSSION

    This is the first clinical study to demonstrate that increasing BIC/FTC/TAF to twice-daily dosing during rifampicin cotreatment achieved sufficient TAF, TFV, and TFV-DP exposures, overcame the interaction and maintained safe TFV levels. We showed that twice-daily TAF with rifampicin resulted in higher or comparable concentrations of TAF and TFV in plasma, and intracellular TFV-DP compared to once-daily TAF post-rifampicin. The regimen achieved high rates of viral suppression with an acceptable safety profile in PWH and TB receiving rifampicin, providing empiric evidence that BIC/FTC/TAF may be used during TB treatment with dose adjustment. Additionally, findings from the parent INSIGHT trial showed adequate bictegravir exposure with the regimen [21].
    Previous studies conducted in healthy individuals, without HIV or TB, reported decreased plasma levels of TAF and its metabolites during, coadministration with rifampicin [10, 11]. The extent to which these findings held in HIV-TB coinfected population coadministered with TAF and rifampicin was not known. Our study contributes empiric data of increased levels of TAF, TFV, and TFV-DP with TAF double dosing during rifampicin cotreatment in PWH and TB. There are several possible reasons for differences with previous studies. First, participants in our study were initiated on the full-course of TB treatment with RHZE/RH and combination BIC/FTC/TAF compared to single-tablet rifampicin in the earlier studies [10, 11]. Secondly, the presence of HIV and TB coinfection may have altered drug disposition pathways compared to healthy individuals. In our study, rifampicin-based TB treatment was initiated about two weeks prior to TAF initiation whereas previous studies used a parallel design [11] or initiated TAF prior to adding single-tablet rifampicin [10]. These differences may account for the conflicting study findings and underscore the need for prospective clinical studies in people with disease.
    The plasma TAF AUC estimates in our study participants, both during and after TB treatment was above the virologic efficacy target of 55 ng·h/mL [22]. Despite considerable variability in our TAF exposures across visits, AUC values were generally within the range reported in other studies [6, 22–25]. The higher TAF exposure observed at week 4 compared with week 12 during rifampicin coadministration was unexpected, particularly as TFV levels were similar at both visits. Early disease-related changes in drug absorption or reduced transporter activity may contribute to this finding [26]. Reduced intestinal P-gp and BCRP expression have been reported in ART-naive PWH compared with individuals without HIV, and these transporter levels returned to normal in PWH on ART [27, 28], which could plausibly explain some of the transient increase in TAF exposure early in treatment. Future research assessing the impact of ART initiation on drug transporter expression and TAF exposure is warranted to explain the differences observed in this study. Importantly, the observed increase in TAF exposure is unlikely to be clinically relevant as our TFV trough concentrations remained much lower than 160 ng/mL, the concentration associated with higher risk for renal toxicity [19].
    Plasma TFV concentrations were relatively low across all visits compared to TFV concentrations observed with published TDF data [6, 22]. This is consistent with the known pharmacology of TAF, which is designed to deliver lower circulating plasma TFV concentrations, while maximizing intracellular delivery to the target cells [4, 6, 22]. The lower plasma TFV levels are an important indication that the favorable bone and renal safety profile of TAF is likely to be preserved even with the twice-daily dosing.
    Once-daily TAF achieves higher PBMC TFV-DP concentrations than standard-dose TDF [4–6, 29]. In our study, intracellular TFV-DP measured from DBS were higher with twice-daily TAF during rifampicin cotreatment than with once-daily TAF post-rifampicin, indicating that twice-daily dosing effectively compensates for rifampicin and maintains exposures sufficient for virologic efficacy. We observed that TFV-DP levels increased between weeks 4 and 12, consistent with the expected continued accumulation of TFV-DP toward steady state. Assuming similar pharmacokinetics to earlier studies [30], the week 4 TFV-DP levels were about 60% of steady-state, while week 12 levels were closer to steady state (∼94%) during the twice-daily dosing with rifampicin. Week 32 TFV-DP levels reflect partial decline during the once-daily dosing period (∼75% of steady state). Therefore, the GLSM ratios we reported are likely conservative, as week 32 concentrations are expected to continue declining until steady state is reached. The TFV-DP concentrations achieved in our participants were lower than in some previous reports [30, 31]. This may be attributable to our use of 3 mm DBS punches for assay, known to yield approximately one-eighth the values reported with 7 mm punches in another study [32]. Importantly, our findings were comparable to other studies after adjusting for punch size [30, 31].
    Recent pharmacokinetic data in PWH and TB suggested that once-daily TAF with rifampicin may be sufficient; in one study, intracellular TFV-DP concentrations were five times higher when TAF was taken with rifampicin compared to standard-dose TDF (without rifampicin), but virological outcomes were not assessed [13]. Moreover, once-daily TAF was only administered for a short period during the continuation phase of TB treatment and there was no concurrent measurement of TAF concentration beyond TB treatment. In another small retrospective study, sustained viral suppression was observed in seven PWH receiving a TAF-containing regimen dosed once-daily with rifampicin, but without accompanying pharmacokinetics data [12]. Given that TAF is available in fixed-dose combination regimens with other antiretroviral drugs that also requires dose-adjustment during TB treatment, our study provides pharmacokinetic and safety data to support twice-daily TAF as part of the efficacious BIC/FTC/TAF regimen during TB treatment. Further studies are required to evaluate TAF in other fixed-dose ART combinations for administration during rifampicin-based TB treatment.
    Our study has several limitations. First, our pharmacokinetic sampling was limited by the design of the parent trial aimed at optimizing pharmacokinetic sampling times for bictegravir, precluding collection of earlier postdose sample times (eg, 0.5 hours); this may have led to the underestimation of TAF AUC and Cmax. TAF has a rapid absorption and short plasma half-life (∼0.5 hours), thus early peak concentrations are important for accurate estimation of exposure. TAF is unstable in plasma, requiring prompt sample processing; while consistent handling was ensured across visits, small deviations could have affected results. TFV-DP was measured from DBS, using 3 mm punches resulting in lower values and limiting comparability with other studies using PBMC or 7 mm punches but this methodology was consistent across visits and therefore allows for intrastudy comparisons. Lastly, we did not measure TFV-DP levels in participants on TDF (in the control arm), which would have enabled a direct comparison between TDF and TAF during rifampicin cotreatment, although the comparison would have been between arms rather than within-arm. Nonetheless, the evaluation of TFV-DP levels during and after TB treatment in the same participants allowed for intraparticipant comparisons, thus allowing us to determine the impact of rifampicin on TAF. The strong virologic outcomes support the robustness of our findings.

    CONCLUSION

    In adults with HIV and TB, twice-daily TAF achieved sufficient exposures to mitigate the enzyme-inducing effects of rifampicin, was effective with an acceptable safety profile. These findings fill an important knowledge gap in the pharmacokinetics of TAF-containing ART during coadministration with rifampicin-based TB treatment and support the use of TAF in a fixed-dose combination of BIC/FTC/TAF given twice-daily among PWH with TB. Furthermore, these data contribute evidence to support expanded access to TAF in Africa and other resource-limited, high TB/HIV burden settings, where its use has been previously limited.
    KDDr. Kelly Dooley
    Leading Voice

    Dr. Kelly Dooley

    Infectious Disease · Mycobacterial Disease
    Vanderbilt Health
    kelly